Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDOptimizeRx Corp Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 4 | -$0.21 | $0.21 | $0.05 |
| Q2 2026 | 4 | $0.08 | $0.15 | $0.11 |
| Q3 2026 | 4 | $0.18 | $0.30 | $0.25 |
| Q4 2026 | 2 | $0.41 | $0.48 | $0.44 |
| Q1 2027 | 2 | $0.12 | $0.15 | $0.13 |
| Q2 2027 | 1 | $0.09 | $0.11 | $0.10 |
| Q3 2027 | 1 | $0.29 | $0.34 | $0.31 |
| Q4 2027 | 2 | $0.54 | $0.63 | $0.57 |
OptimizeRx Corp Earnings Date And Information
OptimizeRx Corp last posted its earnings results on Tuesday, May 12th, 2026. The company reported $0.14 earnings per share for the quarter, topping analysts' consensus estimates of $0.01 by $0.13. The company had revenue of 19.84 M for the quarter and had revenue of 109.43 M for the year. OptimizeRx Corp has generated $0 earnings per share over the last year ($0.27 diluted earnings per share) and currently has a price-to-earnings ratio of 12.42. OptimizeRx Corp has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
OptimizeRx Corp Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 05/13/2026 | Q1 2026 | N/A | -$0.03 | N/A | $18.74 M | $19.84 M |
| 03/12/2026 | Q4 2025 | N/A | $0.27 | N/A | $30.91 M | $32.24 M |
| 11/07/2025 | Q3 2025 | N/A | $0.04 | N/A | $23.55 M | $26.07 M |
| 08/08/2025 | Q2 2025 | N/A | $0.08 | N/A | $22.26 M | $29.20 M |
| 05/13/2025 | Q1 2025 | N/A | -$0.12 | N/A | $18.69 M | $21.93 M |
| 03/20/2025 | Q4 2024 | N/A | -$0.00 | N/A | $30.70 M | $32.32 M |
| 11/14/2024 | Q3 2024 | N/A | -$0.50 | N/A | $24.99 M | $21.31 M |
| 08/15/2024 | Q2 2024 | N/A | -$0.22 | N/A | $20.16 M | $18.81 M |
| 05/15/2024 | Q1 2024 | N/A | -$0.38 | N/A | $18.13 M | $19.69 M |
| 04/15/2024 | Q4 2023 | N/A | -$0.23 | N/A | N/A | $28.37 M |
| 11/06/2023 | Q3 2023 | $0.03 | -$0.17 | -0.2 | N/A | $16.33 M |
| 08/14/2023 | Q2 2023 | -$0.01 | -$0.24 | -0.23 | N/A | $13.82 M |
| 05/12/2023 | Q1 2023 | N/A | -$0.37 | N/A | N/A | $13.00 M |
| 03/10/2023 | Q4 2022 | N/A | -$0.02 | N/A | N/A | $19.65 M |
| 03/10/2023 | Q3 2022 | N/A | -$0.19 | N/A | N/A | $15.09 M |
| 03/10/2023 | Q2 2022 | N/A | -$0.21 | N/A | N/A | $13.98 M |
| 03/10/2023 | Q1 2022 | N/A | -$0.21 | N/A | N/A | $13.73 M |
| 03/10/2023 | Q4 2021 | N/A | $0.04 | N/A | N/A | $20.31 M |
| 11/09/2021 | Q3 2021 | $0.13 | $0.00 | -0.13 | N/A | $16.12 M |
| 08/04/2021 | Q2 2021 | $0.07 | $0.02 | -0.05 | N/A | $13.63 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
OptimizeRx Corp Earnings: FAQ's
In the previous quarter, OptimizeRx Corp (:OPRX) reported $0.14 earnings per share (EPS) to beat the analysts' consensus estimate of $0.01 by $0.13.
The conference call for OptimizeRx Corp's latest earnings report can be listened to online.
The conference call transcript for OptimizeRx Corp's latest earnings report can be read online.
OptimizeRx Corp (:OPRX) has a recorded annual revenue of $109.43 M.
OptimizeRx Corp (:OPRX) has a recorded net income of $5.13 M.OptimizeRx Corp has generated $0.28 earnings per share over the last four quarters.
OptimizeRx Corp (:OPRX) has a price-to-earnings ratio of 12.42 and price/earnings-to-growth ratio is 0.